Skip to main content
. 2016 Apr 18;9(4):269–280. doi: 10.1177/1756285616643892

Figure 2.

Figure 2.

Percentage of patients showing either declined (i.e. falling outside the lower limit of the 5% interval in two or more tests) or stable (including improved) cognitive functions for patients treated with fingolimod(n = 22) and patients treated with natalizumab (n = 11).